PMID- 34410900 OWN - NLM STAT- MEDLINE DCOM- 20220106 LR - 20220425 IS - 1744-5116 (Electronic) IS - 1388-0209 (Print) IS - 1388-0209 (Linking) VI - 59 IP - 1 DP - 2021 Dec TI - Anticancer effect of myristicin on hepatic carcinoma and related molecular mechanism. PG - 1126-1132 LID - 10.1080/13880209.2021.1961825 [doi] AB - CONTEXT: Myristicin is a natural active compound that has inflammatory, antimicrobial and anti-proliferative properties. Yet, its effect on hepatic carcinoma has not been investigated. OBJECTIVE: To explore the role and related molecular mechanism of myristicin in hepatic carcinoma in vitro. MATERIALS AND METHODS: Human hepatic carcinoma cell lines (Huh-7 and HCCLM3 cells) were treated with different concentrations of myristicin (0.5, 1 and 5 mM) for 24, 48 and 72 h. Then, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium assay (MTT), flow cytometer (FCM) analysis and transwell assay were performed to determine cell proliferation, apoptosis and migration/invasion, respectively. Protein levels of B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X (Bax), E-cadherin, N-cadherin and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway-related proteins were detected using Western blot assay. Gene expression was determined using quantitative real time-polymerase chain reaction (qRT-PCR). RESULTS: Myristicin inhibited cell proliferation and induced apoptosis in Huh-7 and HCCLM3 cells; suppressed cell migration and invasion ability, and increased E-cadherin expression and decreased N-cadherin expression, thereby inhibiting epithelial-mesenchymal transition (EMT). Finally, the findings indicated that myristicin decreased phosphorylated (p)-mTOR and p-AKT expression at the protein level. DISCUSSION AND CONCLUSIONS: Myristicin exerts an efficient therapeutic effect on hepatic carcinoma by suppressing PI3K/Akt/mTOR signalling pathway; thus, it may be used as a new potential drug for hepatic carcinoma treatment. FAU - Bao, Hailan AU - Bao H AD - College of Traditional Mongolian Medicine, Inner Mongolia University for Nationalities, Tongliao, China. FAU - Muge, Qi AU - Muge Q AUID- ORCID: 0000-0003-4988-7514 AD - Mengxi Integrative Medicine Division of Respiratory and Critical Care Medicine, Affiliated Hospital of Inner Mongolia University for Nationalities, Tongliao, China. LA - eng PT - Journal Article PL - England TA - Pharm Biol JT - Pharmaceutical biology JID - 9812552 RN - 0 (Allylbenzene Derivatives) RN - 0 (Antineoplastic Agents) RN - 0 (Dioxolanes) RN - 04PD6CT78W (myristicin) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase) RN - EC 2.7.11.1 (AKT1 protein, human) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) SB - IM MH - Allylbenzene Derivatives/administration & dosage/*pharmacology MH - Antineoplastic Agents/administration & dosage/*pharmacology MH - Apoptosis/drug effects MH - Carcinoma, Hepatocellular/*drug therapy/pathology MH - Cell Line, Tumor MH - Cell Movement/drug effects MH - Cell Proliferation/drug effects MH - Dioxolanes/administration & dosage/*pharmacology MH - Dose-Response Relationship, Drug MH - Humans MH - Liver Neoplasms/*drug therapy/pathology MH - Phosphatidylinositol 3-Kinase/metabolism MH - Proto-Oncogene Proteins c-akt/metabolism MH - Signal Transduction/drug effects MH - TOR Serine-Threonine Kinases/metabolism MH - Time Factors PMC - PMC8381892 OTO - NOTNLM OT - EMT OT - PI3K/Akt/mTOR signalling pathway OT - apoptosis OT - invasion OT - migration OT - proliferation COIS- The authors declare no conflict of interest. EDAT- 2021/08/20 06:00 MHDA- 2022/01/07 06:00 PMCR- 2021/08/19 CRDT- 2021/08/19 17:21 PHST- 2021/08/19 17:21 [entrez] PHST- 2021/08/20 06:00 [pubmed] PHST- 2022/01/07 06:00 [medline] PHST- 2021/08/19 00:00 [pmc-release] AID - 1961825 [pii] AID - 10.1080/13880209.2021.1961825 [doi] PST - ppublish SO - Pharm Biol. 2021 Dec;59(1):1126-1132. doi: 10.1080/13880209.2021.1961825.